Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis

Major Fetal Anomaly Clinical Trial

Official title:

Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02255825
• Other study ID #: 140456
• Status: Withdrawn
• Phase: N/A
• Start date: October 2014
• Est. completion date: June 4, 2019

Study information

• Verified date: June 2019
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To gain knowledge about how patients undergoing prenatal diagnosis for a fetal abnormality understand and react to Whole Genome Sequencing (WGS) testing, so that the investigators can develop more ethical and responsible approach to patient education, counseling, and return of results for patients.

Description:

Although whole exome sequencing (WES) was first used for identification of the genetic cause of a disease only in 2009 and whole genome sequencing (WGS) in 2010, and questions remain about their performance as clinical tests, they are already being offered to patients and doctors as a clinical test by several laboratories certified by the US government (14 labs for WES and 5 labs for WGS). The results from WES and WGS can be complex and confusing, even for doctors and scientists who work with this technology on a daily basis; for patients, the process of deciding whether to have WES or WGS testing, undergoing the testing, receiving the results, and trying to use the results for further decision-making could be quite stressful. Currently, this process occurs in an unstandardized fashion, with some patients receiving extensive education and counseling, and others receiving almost none. There is a critical need to identify patient needs and desires in this area, and to develop strategies to satisfy them. The primary goal of this project is to gain knowledge about how patients undergoing prenatal diagnosis for a fetal abnormality understand and react to WGS testing, so that we can develop a more ethical and responsible approach to patient education, counseling, and return of results for patients . In order to do this, we need to evaluate parents' understanding of the utility and limitations of the technology, parents' preferences regarding the types of results they want to receive, and the psychological impact of receiving results from this technology. We will enroll 30 families consisting of a woman carrying a fetus with a major abnormality identified by ultrasound, and the father of the fetus, who have opted for amniocentesis for standard prenatal diagnostic testing (karyotyping, fluorescence in situ hybridization (FISH) and/or microarray testing). Half of the families will serve as controls, who will only have standard prenatal diagnostic testing. For the other half of the families, WGS will be performed in addition to standard diagnostic testing. For all 30 cases, we will perform psychosocial evaluations (including assessments of the subjects' mood, understanding of the technology and preferences for return of results) at the time of enrollment, at the time of return of CLIA-certified genetic testing results (karyotype, FISH, microarray, and/or WGS), and after completion of the pregnancy. In this way, we will learn whether participants are receiving adequate education about next-generation sequencing to make informed choices, what the range of preferences are for return of results in a prenatal population (and whether this changes when new methods for prenatal diagnosis are employed), and whether the use of WGS imposes additional psychological stress compared to standard prenatal diagnostic tests. This study will be carried out in a stepwise and carefully monitored environment, with progress overseen by an Independent Data Monitoring Committee in order to maximize the knowledge gained while minimizing potential harms.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 4, 2019
• Est. primary completion date: June 4, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject(s) 18 years or older (both mom and father of baby (FOB)

• Subject is undergoing prenatal testing for a major fetal anomaly

Exclusion Criteria:

• Mothers or fathers of the affected fetus are under the age of 18 years

Related Conditions & MeSH terms

• Congenital Abnormalities
• Major Fetal Anomaly

Intervention

Genetic:
• Whole Genome Sequencing
Whole genome sequencing in a CLIA lab and return of results.

Procedure:
• Amniocentesis
Note: this is being performed on all subjects as a clinical (not research) procedure

Other:
• Psychosocial assessment
Use of EPDS and STAI for assessment of maternal and paternal mood

Locations

Country	Name	City	State
United States	UCSD Health Sciences, Fetal Care and Genetics	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in maternal mood (focused on assessment of depression)	Compare mood measured by EPDS between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)
Primary	Change in paternal mood (focused on assessment of depression)	Compare mood measured by EPDS between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)
Secondary	Change in maternal mood (focused on assessment of anxiety)	Compare anxiety measured by STAI between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)
Secondary	Change in paternal mood (focused on assessment of anxiety)	Compare anxiety measured by STAI between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)